Why the study?
Do QTc interval-prolonging medications and clinical risk factors increase QTc interval lengthening in a community cohort?
Population
14,160 participants from the Atherosclerosis Risk in Communities study with a resting, standard 12-lead…
Comparison
QTc interval-prolonging medications categorized… vs Absence of QTPMs or absence of risk factors
Design
Cohort
Follow-up
4 examinations at 3-year intervals (1987-1998)
Key result
Risk factors, particularly history of prolonged QTc interval (39 ms) and female sex (12 ms), were associated with greater QTc lengthening than any QTc-prolonging medication category alone.
Authors
Loading...
Risk factors like prior prolonged QTc may warrant prioritized monitoring over medication review alone; leaves open causal effects after adjustment.
Cohort (n=15,792)
Yes
Do QTc interval-prolonging medications and clinical risk factors increase QTc interval lengthening in a community cohort?
Clinical risk factors, particularly female sex and history of prolonged QTc, have stronger associations with QTc lengthening than QTc-prolonging medications alone, though medications further augment this risk.
Alburikan et al. (2017) conducted a cohort in QTc interval lengthening (n=15,792). QTc interval-prolonging medications (QTPMs) and risk factors vs. Absence of QTPMs or risk factors was evaluated on QTc interval lengthening. Risk factors, particularly history of prolonged QTc interval (39 ms) and female sex (12 ms), were associated with greater QTc lengthening than any QTc-prolonging medication category alone.